Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04607018
Other study ID # MMBP_study
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 17, 2015
Est. completion date June 15, 2016

Study information

Verified date October 2020
Source General Hospital Pula
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Panaceo Micro Activation (PMA) -zeolite s a certified medical device throughout the European Union and absorbs defined harmful substances (mainly heavy metals and ammonium ions) in the gastrointestinal tract, while at the same time the alkaline ions contained in the crystal lattice are released (Mg2+, Ca2+, K+, Na+). Through a recent study the main-effect of zeolite was defined (support/ strengthen the intestinal wall barrier) and as a side-effect the measurement of the mineral metabolism was included, without documenting any significant changes. Its potential in releasing minerals needs to be investigated further to broaden the knowledge from previous study-outcomes as described. Broadening this knowledge through measuring defined blood-parameters was the aim of this human trial.


Description:

Background: The ion-loaded natural PMA-zeolite do not act on the body as ion-robber in the digestive tract. The naturally occurring zeolites absorb defined ions in accordance to their selectivity alignment from their surroundings - e.g. in the gastrointestinal tract in the case of the specific certified PMA-zeolite. At the same time the PMA-zeolite absorbs defined harmful substances (mainly heavy metals and ammonium ions) in the gastrointestinal tract, while at the same time the alkaline ions contained in the crystal lattice are released (Mg2+, Ca2+, K+, Na+). Loaded with harmful substances, the zeolite is then excreted through the gastrointestinal tract without interfering with the body's metabolism. The detoxification potential of zeolite was shown in various studies and the safety and efficacy is well documented. The measurement of the mineral metabolism was also included in a randomized controlled trial (RCT). The knowledge about its potential in releasing minerals needs however to be investigated further to broaden the knowledge from previous study-outcomes. Methods/study-subjects: Evaluation of the effect of the PMA-zeolite supplementation through analysis of defined blood-parameters before and after 28 days on two groups of 15 healthy volunteers (males and females) divided in NAiVE (started intake at day 1) and CHRONIC user group (intake of PMA-zeolite min. 28 before study-start). Hypothesis: Due to the defined effect mechanism of PMA-zeolite absorbing harmful substances (contaminants and heavy-metals) in the gastrointestinal tract and release of physiologically important minerals at the same time our hypothesis/ evaluated effects were that the PMA-zeolite has no negative impact on the mineral metabolism and might support. the natural body homeostasis, the measurement of the detoxification ability through a heavy-metal panel and other defined parameters. Aims: Aim of this intervention is hypothesized to lead to improvement of the enumerated values after an application after 28 days (NAiVE group).


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date June 15, 2016
Est. primary completion date May 13, 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - healthy volunteers - at least 18 years old - provided informed consent Exclusion Criteria: - chronic disease including: - cancer, - renal disease, - neuro-degenerative, - metabolic disorders, - diabetic) - recent vaccinations, - pregnancy or breastfeeding, - food supplements (if taken regularly this should be continued also during the study and documented)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
PMA-zeolite
subjects received boxes containing PMA-zeolite powder for supplementation for a total of 28 days. Dosage for PMA-zeolite (100% zeolite; 1 ML - spoon for dosage = ca. 3 g zeolite):1 spoon of the powder stirred 2 times daily (morning and evening) in water (1 glass).

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
General Hospital Pula

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of Liver parameters Biochemical evaluation of LIVER PARAMETERS (aspartate-aminotransferase, alanine-aminotransferase, gamma-glutamyltransferase)
Referent values/range used for analyses:
aspartate aminotransferase (AST): 8-38 U/L (Unit/litre) alanine aminotransferase (ALT): 10 - 48 U/L (Unit/litre) (lower values are not clinically relevant) Gamma-glutamyl transferase (GGT): Men: 11 - 55 U/L (Unit/litre) Woman: 9 - 35 U/L (Unit/litre)
This parameters will be combined to report the LIVER function
The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups
"Day 0" and "Day 28"
Primary Changes of renal parameters Biochemical evaluation of RENAL PARAMETERS (creatinine, evaluation of the glomerular filtration speed will be done by use of a specific formula)
Referent values/range used for analyses:
CREAT: Woman: 63 - 107 µmol/L, Men: 79 - 125 µmol/L glomerular filtration (GF) - evaluation: G1>=90/ G2 60-80/G3a 45-59/G3b 30-40/G4 15-29/G5 <15. M: 11-32; F:8-30 µmol/l
This parameters will be combined to report the RENAL function
The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups
"Day 0" and "Day 28"
Primary Changes of main standard mineral level in the blood Evaluation of standard mineral panel
Analyses:
Na and K assessment relie on indirect potentiometer analysis Zn concentrations in serum assessed by use of spectrophotometric method Biochemical evaluation of Fe, Ca and Mg were done by standard spectrophotometric methods.
Evaluation of the glomerular filtration speed will be done by use of a specific formula.
Referent values/ range used:
Na: 137 - 146 mmol/L; K: 3,9 - 5,1 mmol/L; Zn: Men: 11,1-19,5 µmol/l, Woman:10,7-17,5 µmol/l; Fe: Men:11-32; Woman:8-30 umol/l Mg: 0,65 - 1,05 mmol/L Ca: 2,14 - 2,53 mmol/L
The parameters will be combined for evaluation of the mineral metabolism
The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups
"Day 0" and "Day 28"
Primary Changes of main metal level in the blood Evaluation of main mineral panel
for Pb, Hg, Cr, Cd, As, Al and Ni were inductively Coupled Plasma Mass Spectrometry-ICP-MS analysis of serum and plasma samples
Referent values/range used:
Lead (Pb) = 50 µg/L Mercury (Hg) <10 µg/L Cadmium (Cd) < 1 µg/L Chromium (Cr) < 1 µg/L Arsenic (As) < 12µg/L Aluminium (Al) < 8 µg/L Nickel (Ni) < 2 µg/L
The parameters will be combined for evaluation of the metal level
The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups
"Day 0" and "Day 28"
Primary Changes of Meathemoglobin in the blood Methemoglobinemia is a condition of elevated methemoglobin in the blood causing headache, dizziness, shortness of breath, nausea....
Analyses for MHgb - methaemoglobin: The method relies on CO-oximetry by use of GEM OPLTM analyser
Referent values/range used for analyses: methaemoglobin (MHgb) : 0-1,5%
The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups
"Day 0" and "Day 28"
See also
  Status Clinical Trial Phase
Recruiting NCT05100615 - Healing Assessment of Osseous Defects After Surgical Removal of Periapical Lesions N/A
Completed NCT05445362 - Efficacy of Diode Laser in Maturogenesis of Immature Teeth With Necrotic Pulps N/A
Completed NCT04761211 - Effect and Safety of Smart Bra (PUMCH) N/A
Recruiting NCT04338633 - Post-operative Pain Reduction N/A
Recruiting NCT04327453 - Effect of Removal of Double Antibiotic Paste on Post Operative Pain N/A
Recruiting NCT04324086 - Effect of Removal of Intracanal Medication on Post Operative Pain N/A